Celcuity Inc. (CELC)
- Previous Close
17.54 - Open
17.56 - Bid 17.21 x 400
- Ask 17.35 x 100
- Day's Range
17.18 - 18.21 - 52 Week Range
8.39 - 22.19 - Volume
90,262 - Avg. Volume
219,583 - Market Cap (intraday)
525.011M - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-2.69 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.60
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
www.celcuity.comRecent News: CELC
Performance Overview: CELC
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CELC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CELC
Valuation Measures
Market Cap
525.62M
Enterprise Value
382.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.76
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.56
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.56%
Return on Equity (ttm)
-46.63%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-63.78M
Diluted EPS (ttm)
-2.69
Balance Sheet and Cash Flow
Total Cash (mrq)
180.58M
Total Debt/Equity (mrq)
26.79%
Levered Free Cash Flow (ttm)
-35.62M